Nano cap Cesca Therapeutics (KOOL +26.2%) shows bullish price action with today's up move on a 10x surge in volume. It represents a successful retest of the January 21 breakout when prices popped 111% on massive turnover of 32.9M shares after the company announced positive Phase 1b clinical trial results for its stem cell therapy for critical limb ischemia.
The company acquired development partner TotipotentRX shortly thereafter and changed its name from Thermogenesis.
Last month, it submitted a pre-IDE information package to the FDA for the product, now called SurgWerks, as the first step in its commercialization efforts in the U.S.
Considering its microscopic market cap of $66M, retail investors should insist on thorough due diligence before considering deploying capital.